Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
I’d suggest they left SGS as employees to go with OO as partners (own Ltd company)
'The UK has agreed to buy up to 60m doses of a vaccine being developed by Sanofi and GlaxoSmithKline if the companies are able to prove its efficacy against Covid-19 in clinical trials to start in September.'
Hmmm, the September timeframe again,,,, perhaps, just perhaps, they may be conducting trials with a well known specialist services company in this area? (not ramping)
CF is on holiday, confirmed on yesterdays interview, however he also has a COO, CFO & CSO, so i shouldn't worry too much about it, it doesn't stop the wheels turning or the pipeline of contracts being signed.
(Berkwickman - insert mandatory insult just here please).
At least we have proof he’s not in clubbing in Ibiza ;)
I'm not ramping, i am being positive,,, it's infectious and you don't need a challenge study for it to work, try it mate and good luck
CF also said on a presentation that they have capability to use another 100 bed facility if needed. Not an issue.
A "steady pipeline of news" don't forget, this is just the start - confirmation in my view that we have a challenge agent enabling faster vaccine development, its the first hour of trading on this news, this is only going one way from here, massive positives for myself. Good luck all
I am pretty sure with Acacia out and on this news this is going to re-rate, today will be a good test for this theory. To me the big news is that we have a challenge agent developed, another huge de-risk development for me.
With this news, would it be logical to assume that we now have a challenge agent developed for future Covid challenge studies?
Open Orphan plc
("Open Orphan" or the "Company")
Awarded Contract from Codagenix Inc. New York USA for COVID-19 Vaccine Trial
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. ("Codagenix") to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers.
Highlights:
· First in human (Phase I) study of CodaVax-COVID, a codon deoptimized SARS-CoV-2 (COVID-19) single-dose, intranasal vaccine candidate
· Vaccine being trialled at hVIVO's state-of-the-art Quarantine Facility in Whitechapel in London
· Phase I study to start in early Autumn with initial data expected by the end of 2020
· Study will include second dose as surrogate viral challenge at Day 28
hVIVO, part of Open Orphan, will conduct the COVID-19 vaccine trial for Codagenix at its state-of-the-art Quarantine Facility. CodaVax-COVID is a live-attenuated vaccine that replicates very slowly, but contains all SARS-CoV-2 proteins, unlike most other vaccines that only contain the viral spike. This vaccine has the potential to induce broad antibody, cellular and mucosal immunity with a single intranasal dose. hVIVO is currently kicking off the initial steps of this exciting study and are expected to start the trial in the quarantine unit this autumn.
This contract reinforces Open Orphan's position as the world leader in the testing of vaccines and antivirals.
Cathal Friel, Executive Chairman, Open Orphan, said:
"We are proud to be conducting this Phase I study for Codagenix, a leader in their field, as it will help bring a promising vaccine candidate to the public to help combat the COVID-19 pandemic as quickly as possible.
hVIVO, with its unique quarantine facility, is one of the few organisations in the world that has now publicly stated that it is working on testing COVID-19 vaccines for efficacy using human challenge model clinical trials.
Today's announcement also shows that hVIVO's quarantine facility is uniquely suited to conducting Phase I studies for infectious disease vaccines such as this.
Codagenix's expertise in viral design technology, combined with hVIVO's Phase I trial capability, gives us confidence that this trial will be successful and a step forward for the world as it seeks to develop a COVID-19 vaccine to bring the pandemic to a close."
Sybil Tasker, MD, MPH, Chief Medical Officer of Codagenix, said:
"We are very excited to be collaborating with hVIVO for the first-in-human study of CodaVax-COVID. hVIVO is world-recognized for expertise in evaluation of live viruses in human volunteers. Based on our animal data we expect this vaccine to be ef
RNS OUT
I shorted my bet Swap;) good luck, we are on the move
I hear (but not confirmed on twitter yet) that he has a repetitive strain injury from signing contracts, this is stopping him from updating the tinterweb maybe?
That tweet is a windup, i'd have CF down as a South of France man myself, maybe Cannes?
He's presenting again on August 5th, i'll show my backside in Woolworths window if there isn't news on at least one deal before then.
Its time you owned up Swap, Cathal is that you?
I think because every time this share got the attention and volume to breakout, it was killed by the acacia offload, this share will breakout and re-rate on the next news that brings attention to it. If, as CF states there will be a pipeline of news, then the move north is only a matter of time.
Sorry swap, how about,,,, making money with Orph, is as easy as selling life jackets on a sinking ship!
Watch this space